Basal Innovation Team_NSM 2018
1. DEVOTE trial was conducted to
Establish the superior glycemic efficacy of insulin degludec over insulin glargine
Establish lesser risk of hypoglycemia with glargine compared to degludec
Establish the lesser insulin dose requirement and weight gain with degludec compared to glargine
Establish the cardiovascular safety of insulin degludec compared to insulin glargine
2. Which of the below figures are true for DEVOTE?
Number of trial sites from India were 36
Number of participants from India were 357
Number of countries that participated in the trial were 40
The country that recruited second highest number of participants to the trial was UK
3. Which of the below is false about DEVOTE trial
DEVOTE stands for Degludec cardiovascular outcomes trial
7637 patients were included in the trial
DEVOTE was an open label, randomized controlled trial
The number of major adverse cardiovascular outcomes that occurred in DEVOTE were 633
4. Which of the below is true about the baseline characteristics of DEVOTE?
Mean baseline HbA1c was 8.4%
Mean duration of type 2 diabetes was ~14 years
55% of the patients had established CV disease or CKD
Mean BMI was 23.4 kg/m2
5. The analysis of the primary endpoint of the DEVOTE showed that
There is a 30% significant reduction in CV outcomes with degludec compared to glargine
There is a 9% significant reduction in CV outcomes with degludec compared to glargine
There is a 9% numerical reduction in CV outcomes with degludec compared to glargine, not significant
Degludec proved cardiovascular benefits for 3-point MACE compared to glargine
6. In the DEVOTE, the incidence rates of severe hypoglycemia was
40% significantly lower with degludec Vs glargine
27% significantly lower with degludec Vs glargine
53% significantly lower with degludec Vs glargine
40% numerically lower with degludec Vs glargine, not significant
7. In the DEVOTE, the event rates of severe hypoglycemia was
40% significantly lower with degludec Vs glargine
27% significantly lower with degludec Vs glargine
53% significantly lower with degludec Vs glargine
40% numerically lower with degludec Vs glargine, not significant
8. In the DEVOTE, the event rates of nocturnal severe hypoglycemia was
40% significantly lower with degludec Vs glargine
27% significantly lower with degludec Vs glargine
53% significantly lower with degludec Vs glargine
40% numerically lower with degludec Vs glargine, not significant
9. The FPG control in DEVOTE was ______ with degludec compared to glargine
7.2 mg/dl, significantly lower
Similar
7.2 mg/dl, significantly worser
17.2 mg/dl, significantly lower
10. DEVOTE 2 trial measured which type of glycemic variability?
Day-to-day fasting glycemic variability
Within day fasting glycemic variability
Overall throughout the day glycemic variability
Post-prandial glycemic variability
11. DEVOTE 3 trial measured association between
Severe hypoglycemia and microvascular complications
Severe hypoglycemia and death
Glycemic variability and MACE
Glycemic variability and all-cause death
12. As per DEVOTE 2, patients with higher glycemic variability had
A 33% higher risk of baseline adjusted all-cause mortality
A 23% higher risk of baseline adjusted all-cause mortality
A 13% higher risk of baseline adjusted all-cause mortality
A 43% higher risk of baseline adjusted all-cause mortality
13. The DEVOTE 3 trial showed that, following an episode of severe hypoglycemia
The risk of all-cause death increased by 121% and CV death by 154%
The risk of all-cause death increased by 154% and CV death by 121%
The risk of all-cause death increased by 151% and CV death by 114%
The risk of all-cause death increased by 114% and CV death by 151%
14. Mechanism of protraction of glargine U300 is by formation of
Smaller precipitates and larger surface area
Larger precipitates and larger surface area
Smaller precipitates and smaller surface area
Larger precipitates and smaller surface area
15. Glargine U300 showed a benefit in hypoglycemia over glargine U100 in
T1D patients
Early insulin-naïve T2D patients
Patients using low dose of basal insulin
Patients using high dose of basal insulin with late diabetes
16. When compared to glargine U300, insulin degludec has
4 times higher day-to-day variability
37% lower within day variability
30% lower potency
Less even distribution of glucose lowering effect over 24 hours
17. Which of the following is untrue about the MI Basal market
Basal initiations consist the bulk of all insulin initiations
Lantus has the largest prescription share among all brands
Most prescriptions were gained by Basugine in 2017 over 2016
Tresiba® has around ~3% prescription share
18. Which of the following are true about the new switching guidelines for Tresiba?
While switching from OD Gargine U100 to Tresiba reduce dose by 20%
While switching from glargine U300 to Tresiba reduce dose by 20%
While switching from BD glargine U100 to Tresiba reduce dose by 20%
In T1D While switching from glargine U100 to Tresiba reduce dose by 20%
19. Which of the following is not a part of the Tresiba summary page in iselling?
Once daily ultra long duration of action beyond 42 hours
Similar HbA1C control to insulin glargine in treat-to-target studies
Significantly lower risk of nocturnal hypoglycaemia
20. Day-to-day variability improved in______ of patients after switch from IGlar U300 to IDeg
50%
30%
86%
10%
21. Which of the following factors are considered for career progression from a Product Specialist to a Sr product specialist?
3P Rating
Minimum years of experience
Recommendation form Line manager
All of the above
22. Which of the following options regarding Goal Setting is completely TRUE for 2018 process:
1. Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 5 goals with minimum 10% weight
2. Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 10 goals with minimum 5% weight
3. Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 10 goals with minimum 5% weight
4. Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 12 goals with minimum 5% weight
23. Which of the following statements is FALSE for 2018 performance management process
Your performance rating will impact your annual salary increase
Your performance rating will not impact your selection to development programmes
Your 3P rating will serve as an input for career progression
Your performance rating will be solely decided by your manager’s discretion
25. Which of the following statements is true for 2018 Talent Development Program Nomination?
Your performance rating will be considered for your nomination
Your performance rating along with manager’ inputs will be considered for your nomination
Your cumulative health score card will be considered for your nomination
Your sales performance will be considered for your nomination
26.All employees should report any customer complaint (Product defect/AE/SAE) or safety information to
Safety Team (INAGREE@novonordisk.com)
GM (General Manager)
HQ (Head Quarters)
None of the above
27. Which of the below need to be reported ( mark the correct)
Use of NN product in pregnancy
Any technical complaint
Any adverse Event
All the above
28. If an HCP requests for off label information you should contact
GM
Medical Department
Finance Department
Do not know
29. In case if you observe errors in label, promotional material contact ( mark the correct)
Line Manager & QA
No need to report to any one
Distribute to HCP with error
Do not know
30. Corrections to printed or handwritten data must be made so that the original text is
Strikethrough so nothing is readable
Strikethrough but readable
Completely covered using a whitener
Enter duplicate data
31. In NN, we follow any applicable laws, regulations and industry codes. We also follow our own business ethics standards and procedures (Novo Nordisk Code of Conduct). According to the Business Ethics Code of Conduct, which of the following statements is correct?
Local law and industry code may be disregarded, if my local legal department approves it
Novo Nordisk standards and procedures may be overruled if more stringent rules apply locally
Either of the above
32. An employee invites an HCP as a speaker for a meeting to be held on 20th August 2017. You send the request for contract preparation to the legal department by filling up the contract initiation template. Amount to be paid for the services is INR 50,000. When you will calculate FMV?
At the time of payment
At the time of preparation of the contract
Either of the above
None of the above
33. In a Sponsorship, the following is acceptable:
Payment routed to HCP’s directly need not include any follow up documentation
While Sponsoring an event, commercial benefit for Novo Nordisk and disclosure of the fact that the event has been sponsored by Novo Nordisk is not required if sponsorship amount is below INR 5,00,000.00
Follow up on fund utilisation is not required if sponsorship amount is below INR 5,00,000.00
The commercial benefit to Novo Nordisk, disclosure of the fact that the event has been sponsored by Novo Nordisk, agreement and proper follow-up documentation from the institution.
34. Ryzodeg meeting took place on 1st July 2017. Timings as per agenda was 8:00 to 10:00 PM, with dinner scheduled from 9:30 to 10:00 PM. Due to unavoidable circumstances, meeting started at 8:30 PM. Meeting ended at 10:45 pm. But hotel invoice was generated at 12:00 pm. How will you abide by 75/25 rule for the scientific meeting?
I will inform Manager and pay the hotel as per his instructions
I will pay the hotel and thereafter raise exception for deviation from 25/75 rule and document the reason for delay in the start of the meeting
There is no deviation as such in the situation as it occurred due to unavoidable circumstances
None of the above
35. An employee invites a doctor (HCP) as a speaker for a meeting. The HCP accepts the invitation. He is accompanied to the meeting by his friend, who is also a doctor and practices in the field of endocrinology.
It can be accommodated as the friend is also a doctor.
Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies.
Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies. If the friend still attends the event, you should document it
36. What is the Incentive amount you are eligible at 100% sales achievement p.a (Both Sales & Activity)?
200000
250000
700000
None of the Above
39. What is the maximum incentive you can earn per annum (Both Sales & Activity)?
250000
600000
700000
None of the Above
41. Novorapid is produced by
Substitution of B29 amino acid proline with aspartic acid
Deletion of B30 amino acid threonine
Adding fatty di-acid side chain at B29 position
Substitution of B28 amino acid proline with aspartic acid
42. Pharmacokinetic profile of novorapid as compared to Actrapid:
Lesser Tmax, higher Cmax
Lesser Tmax, lesser Cmax
Higher Tmax, higher Cmax
Higher Tmax, higher Cmax
44. What is the advantage of adding protamine crystal?
To decrease hypoglycemia
To decrease PPG
To enhance duration of action
No advantage
47. In Heller study as compared to HI with Novorapid there was 72% reduction in?
Minor hypoglycemia
Nocturnal hypoglycemia
Severe nocturnal hypoglycemia
{"name":"Basal Innovation Team_NSM 2018", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"1. DEVOTE trial was conducted to, 3. Which of the below figures are true for DEVOTE?, 2. Which of the below is false about DEVOTE trial","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}